AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker announced Monday. The Britain based pharma giant said the expanded ...

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...

PT027 and the albuterol comparator were delivered in a pressurised metered-dose inhaler using AstraZeneca’s Aerosphere delivery technology. Results showed that PT027 at the 180mcg albuterol ...

UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new "next generation" inhaler with a propellant that reduces Global ...

AstraZeneca) to a dry-powder inhaler (fluticasone-salmeterol, Wixela Inhub; Viatris). All included patients had a combination inhaler prescription prior to the dry-powder inhaler switch ...

AstraZeneca recently announced the completion of clinical studies for a next-generation propellant (NGP) version of its chronic obstructive pulmonary disease (COPD) inhaler, Breztri. This new ...